18th Sep 2014 15:24
LONDON (Alliance News) - Clinigen Group Thursday said it has launched its new injectable antibiotic Vibativ in Europe which aims to treats adults with nosocomial pneumonia, also known as hospital acquired pneumonia.
Hospital acquired pneumonia is the most common cause of death among infections acquired in a hospital setting, the company said.
Clinigen said Vibativ offers a dual mechanism of action enabling it to kill even drug resistant strains of Staphylococcus aureus. Staphylococcal infections are a group of infections caused by the bacterium Staphylococcus
"The drug's dual mechanism of action means that even a strain resistant to one of the mechanisms of action may still be affected by the other mechanism, suggesting that Vibativ may be less prone to resistance than other antibiotics," the company said.
The stock was quoted up 0.4% at 463.75 pence Thursday afternoon.
By Anthony Tshibangu; [email protected]; @AnthonyAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
CLIN.L